The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb; Genexine; Lilly
Consulting or Advisory Role - Bayer; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Green Cross (Inst); LSK BioPharma (Inst); MacroGenics (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); Y-Biologics (Inst); Zymeworks (Inst)
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
 
Daniel V.T. Catenacci
Honoraria - Amgen; Archer; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Natera; Pieris Pharmaceuticals; QED Therapeutics; Seagen; Taiho Pharmaceutical; Tempus; Zymeworks
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech/Roche; Guardant Health; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation Medicine; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Exelixis; Five Prime Therapeutics; Merck Sharp & Dohme; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Keun-Wook Lee
No Relationships to Disclose
 
In-Ho Kim
No Relationships to Disclose
 
Sang Cheul Oh
No Relationships to Disclose
 
Jin Li
Speakers' Bureau - AstraZeneca; Lilly
 
Haci M. Turk
No Relationships to Disclose
 
Alexandra Carolina Teixeira
No Relationships to Disclose
 
Christophe Borg
Consulting or Advisory Role - MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Bayer; MSD
 
Erika Hitre
No Relationships to Disclose
 
Anghel Adrian Udrea
Travel, Accommodations, Expenses - Amgen; Angellini; Janssen; Merck Sharp & Dohme; PFIZER; Roche
 
Giovanni Gerardo Cardellino
Travel, Accommodations, Expenses - Lilly; MSD; Roche
 
Raquel Guardeno
No Relationships to Disclose
 
Siddhartha Mitra
Employment - Five Prime Therapeutics; Gilead Sciences
Stock and Other Ownership Interests - Five Prime Therapeutics; Gilead Sciences
 
Yingsi Yang
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
 
Peter C. Enzinger
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Celgene; Daiichi Sankyo; loxo; Merck; Taiho Pharmaceutical; Takeda; Zymeworks
 
Zev A. Wainberg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck